10-Q: SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Clinical Program Update

SELLAS Life Sciences Group reported its financial results for the second quarter of 2024, highlighting clinical trial progress and recent capital raising activities.

Summary

• SELLAS Life Sciences Group, a clinical-stage biopharmaceutical company, announced its financial results for the quarter ended June 30, 2024.
• The company reported a net loss of $7.47 million for the three months ended June 30, 2024, and a net loss of $17.036 million for the six months ended June 30, 2024.
• Research and development expenses were $5.186 million for the three months and $10.297 million for the six months ended June 30, 2024.
• General and administrative expenses were $2.435 million for the three months and $6.969 million for the six months ended June 30, 2024.
• The company completed enrollment in its Phase 3 REGAL study for GPS in AML and expects an interim analysis by the fourth quarter of 2024.
• Positive topline data was reported from the Phase 2a clinical trial of SLS009 in combination with aza/ven in r/r AML, with a 100% response rate in patients with ASXL1 truncating mutations in the 30mg BIW cohort.
• SELLAS completed several capital raises, including a registered direct offering in August 2024, raising approximately $19.5 million, and other offerings in March and January 2024.
• As of June 30, 2024, the company had cash and cash equivalents of approximately $9.1 million and restricted cash and cash equivalents of $0.1 million.
• The company expects its cash and cash equivalents, together with the net proceeds from the August 2024 Registered Direct Offering, will not be sufficient to fund its current planned operations for at least the next twelve months.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive clinical trial updates and successful capital raises, the company's financial position and the need for additional funding raise concerns. The ongoing arbitration also adds uncertainty.

Positives

• The company completed enrollment in the Phase 3 REGAL study, a significant milestone for the GPS program.
• The Phase 2a trial of SLS009 showed promising results, particularly in patients with ASXL1 mutations.
• The company successfully raised capital through multiple offerings, strengthening its financial position.
• SELLAS has secured Orphan Drug and Fast Track designations for both GPS and SLS009, which could expedite regulatory approvals.
• The company has expanded the ongoing SLS009 study to include additional cohorts based on biomarker findings.

Negatives

• The company reported a net loss of $17.036 million for the six months ended June 30, 2024.
• The company's cash and cash equivalents are not expected to be sufficient to fund operations for the next twelve months.
• SELLAS is involved in an arbitration proceeding with 3D Medicines, which could result in additional costs and uncertainty.
• The company has an accumulated deficit of $234.3 million as of June 30, 2024.

Risks

• The company's ability to continue as a going concern is dependent on securing additional funding.
• Clinical trial outcomes are uncertain, and there is no guarantee of regulatory approval for product candidates.
• The arbitration proceeding with 3D Medicines could have a negative impact on the company's financials.
• The company faces competition from other biotechnology and pharmaceutical companies.
• The company's future success depends on the successful development and commercialization of its product candidates.

Future Outlook

The company expects to continue to generate operating losses and negative cash flows from operations for the next few years and will need additional funding to support its planned operating activities through profitability. The company expects its cash and cash equivalents, together with the net proceeds from the August 2024 Registered Direct Offering, will not be sufficient to fund its current planned operations for at least the next twelve months.

Management Comments

• The Independent Data Monitoring Committee projects with a high level of confidence that the interim analysis (60 events) of the REGAL study will occur by the fourth quarter of 2024.
• Observed efficacy outcomes for SLS009 in the Phase 2a trial exceeded the targeted ORR of 20% and targeted median overall survival of 3 months.

Industry Context

The company is operating in the competitive biopharmaceutical industry, focusing on novel cancer therapeutics. The progress of its clinical trials and the positive data reported for SLS009 are significant in the context of the ongoing search for effective cancer treatments. The company's focus on specific biomarkers, such as ASXL1, aligns with the industry trend towards personalized medicine.

Comparison to Industry Standards

• SELLAS's Phase 3 REGAL study for GPS in AML is comparable to other late-stage clinical trials in the hematological oncology space, such as those conducted by companies like Jazz Pharmaceuticals and Agios Pharmaceuticals, which also target specific mutations or pathways in AML.
• The Phase 2a trial of SLS009, a CDK9 inhibitor, is being conducted in a space where other companies like Syros Pharmaceuticals and Constellation Pharmaceuticals are also developing CDK inhibitors, but SELLAS's focus on ASXL1 mutations and the observed response rates are notable.
• The company's financial position, with a need for additional funding, is common among clinical-stage biopharmaceutical companies, many of which rely on capital raises and partnerships to fund their operations, similar to companies like Kura Oncology and Deciphera Pharmaceuticals.

Legal Proceedings

• The company commenced a binding arbitration proceeding against 3D Medicines regarding milestone payments and development efforts.

Stakeholder Impact

• Shareholders face the risk of dilution due to potential future capital raises.
• Employees may be affected by potential cost-cutting measures if the company fails to secure additional funding.
• Patients may benefit from the development of new cancer treatments if the company's clinical trials are successful.
• Creditors face the risk of non-payment if the company's financial situation does not improve.

Next Steps

• The company will continue to advance the development of GPS and SLS009.
• The company expects an interim analysis of the REGAL study by the fourth quarter of 2024.
• The company will provide additional topline data updates from the Phase 2a trial of SLS009 in the third quarter of 2024.
• The company will continue to pursue discussions with global and regional pharmaceutical companies for licensing and/or co-development rights to its product candidates.
• The company will continue to seek additional funding to support its operations.

Key Dates

Keywords

SELLAS Life Sciences, Galinpepimut-S, SLS009, AML, CDK9 inhibitor, clinical trial, biopharmaceutical, immunotherapy, cancer, ASXL1 mutation, capital raise